Genoa Ventures

Genoa Ventures is a small, focused fund that punches well above its check size in early-stage life sciences. Based in San Francisco and led by Jenny Rooke, who founded the firm after years investing at the Bill and Melinda Gates Foundation and at Fidelity Biosciences, Genoa invests in life sciences tools, diagnostics, and biotech at seed and Series A. Lead checks run from $500K to $5M, which makes the firm one of the more disciplined participants in early life sciences, where capital intensity often pushes funds into larger initial commitments. The firm’s specific focus on tools, molecular diagnostics, and synthetic biology gives it an unusually clear thesis in a sector where most early-stage investors hedge across multiple sub-verticals.

The stated focus areas are life sciences tools, diagnostics, and biotech, with Rooke’s particular interest in molecular diagnostics and synthetic biology giving the firm a distinct flavor. The implied target company is a small team, often a recent academic spinout, building tools or platforms that enable downstream therapeutic, diagnostic, or research applications. Tools companies are favored over therapeutics in the firm’s actual deal pattern, reflecting the capital efficiency advantages of tools businesses: shorter time to revenue, lower regulatory burden, and clearer commercial milestones. Synthetic biology positions tend to focus on platforms with defined application targets rather than open-ended discovery plays. Founders pitching pure therapeutics with multi-year clinical timelines are likely to find better fits at larger biotech-specialist firms.

With specific portfolio names not enumerated in the structured record, founders should review the Genoa Ventures portfolio page directly to map current positions. Patterns to watch for include investments in next-generation sequencing applications, novel molecular diagnostic methods, single-cell biology tools, synthetic biology platforms targeting industrial or therapeutic applications, and lab automation infrastructure. The firm’s positioning suggests a preference for technical defensibility rooted in IP and scientific moat rather than for commercial scale at the time of investment. Founders should expect diligence to weight the underlying scientific differentiation and the founder’s technical credibility heavily.

Check size of $500K to $5M as lead positions Genoa as a seed lead in life sciences tools and a meaningful co-investor at Series A. The firm typically leads small seed rounds and follows into larger Series A rounds led by life sciences specialists. With a smaller fund size compared to mega-firms in the sector, Genoa is unlikely to lead Series A in capital-intensive therapeutics or diagnostics requiring large clinical programs, but it is well-positioned to lead seed and to participate in subsequent rounds for portfolio winners. Co-investment patterns include other early-stage life sciences specialists, university affiliated funds, and selected angels and family offices with life sciences operating backgrounds.

Decision-making at Genoa is concentrated around Jenny Rooke, with the small team structure meaning founders engage directly with senior leadership throughout the process. Rooke’s background spans foundation-funded global health investing at the Gates Foundation and traditional biotech venture at Fidelity Biosciences, which gives her diligence a combination of scientific rigor and practical commercial perspective. Founders should expect direct, substantive conversations with Rooke as the primary decision-maker rather than a long process running through associates and principals.

Warm intros from academic founders Rooke has previously backed, from co-investors at other early-stage life sciences firms, and from senior figures in the synthetic biology and tools communities carry the most weight. Rooke is publicly active in life sciences investing circles, with podcast appearances on shows such as Synbiobeta and Bio Eats World, speaking engagements at conferences including SynBioBeta and AdvaMed, and writing on early-stage life sciences strategy. Founders can use her public commentary to calibrate language and to identify which technical themes are currently most resonant. Cold inbound through the firm’s website is plausible for founders with strong technical backgrounds, but warm relationships substantially improve odds.

Approach Genoa Ventures when you have an early-stage life sciences tools, diagnostics, or synthetic biology company with strong technical differentiation and a credible commercial hypothesis. Do not approach for late-stage rounds, for capital-intensive therapeutics, for digital health software without scientific anchoring, or for medical devices outside the diagnostic space. Among portfolio founders, the firm has a reputation for sharp technical diligence and for genuinely engaged early support, with Rooke personally involved in board work and strategic decisions. For founders building in tools, molecular diagnostics, and synthetic biology at seed, Genoa is one of the more credible specialist options at its check size, and the firm’s focused thesis means founders who fit will get a more substantive conversation than they would at a generalist seed firm.